Review Article

Potential Role of MicroRNA-375 as Biomarker in Human Cancers Detection: A Meta-Analysis

Table 2

QUADAS assessment for the eligible studies.

Enrolled studyItems of QUADAS
(1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)

Gao/2016NYYYYYYYNUUYNN
Erbes et al./2015NYYYUUYYNUYYUY
Wach et al./2015NYYYYYYYUUYYUY
Roberts et al./2015NYYYYYYYYUYUUY
Kachakova et al./2015NYYYYYYYYUYYUY
Yin et al./2015NYYYYYYYYUYYUY
Li et al./2015NYYYYYYYYUYYUY
Carlsen et al./2013NYYYYYYYUUYYUY
Cheng et al./2013NYYYNUYYNUYUUY
Haldrup et al./2013NYYYYYYYYUYUUY
Zhang et al./2012NYYYYYYYYUYYUY
Komatsu et al./2011NYYYYYYYYUYUUY

(1) Was the spectrum of patients representative of the patients who will receive the test in practice? (2) Were selection criteria clearly described? (3) Is the reference standard likely to correctly classify the target condition? (4) Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests? (5) Did the whole sample or a random selection of the sample receive verification using a reference standard of diagnosis? (6) Did patients receive the same reference standard regardless of the index test result? (7) Was the reference standard independent of the index test (i.e., the index test did not form part of the reference standard)? (8) Was the execution of the index test described in sufficient detail to permit replication of the test? (9) Was the execution of the reference standard described in sufficient detail to permit its replication? (10) Were the index test results interpreted without knowledge of the results of the reference standard? (11) Were the reference standard results interpreted without knowledge of the results of the index test? (12) Were the same clinical data available when test results were interpreted as would be available when the test is used in practice? (13) Were uninterpretable/intermediate test results reported? (14) Were withdrawals from the study explained?